Moderna (MNRA) has just invented a new vaccine. Given the phenomenal market response to this product, MNRA is reinvesting all of its earnings to expand its operations. Earnings were $3.75 per share this past year and are expected to grow at a rate of 18.0% per year until the end of year 4. At that point, other companies are likely to bring out competing products. Analysts project that at the end of year 4, MNRA will cut investment and begin paying 55% of its earnings as dividends and its growth will slow to a long-run rate of 2.7%. If MNRA's equity cost of capital is 12.50%, what is the value of a share today